scispace - formally typeset
W

Wen-Juan Fu

Researcher at Third Military Medical University

Publications -  16
Citations -  321

Wen-Juan Fu is an academic researcher from Third Military Medical University. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 7, co-authored 15 publications receiving 236 citations.

Papers
More filters
Journal ArticleDOI

Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells.

TL;DR: A crucial role of autophagy is demonstrated in the formation of VM by GSCs, which may serve as a therapeutic target in drug-resistant glioma.
Journal ArticleDOI

High‐mobility group box 1 released by autophagic cancer‐associated fibroblasts maintains the stemness of luminal breast cancer cells

TL;DR: In this article, the authors found that the presence of CAFs containing high levels of microtubule-associated protein 1 light chain 3 (LC3II), a marker of autophagosomes, was associated with more aggressive luminal human breast cancer.
Journal ArticleDOI

Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma

TL;DR: Investigation of expression of MPC1 and MPC2 in specimens from RCC patients and results identify anti-tumor function ofMPC1 in RCC and reveal MPC 1 as a novel prognostic biomarker to predict better patient survival.
Journal ArticleDOI

Low-dose microcystin-LR antagonizes aflatoxin B1 induced hepatocarcinogenesis through decreasing cytochrome P450 1A2 expression and aflatoxin B1-DNA adduct generation

TL;DR: Co-exposed to microcystin-LR significantly repressed the AFB1 induced malignant transformation of human hepatic cells and the glutathione S-transferase Pi positive foci formation in rat livers, suggesting that when co-exposure with AFB1, MC-LR might repress hepatocarcinogenicity of AFB1.
Journal ArticleDOI

ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN‐deficient primary human glioblastoma

TL;DR: It is identified that ADP‐ribosylation factor like‐4C (ARL4C) was highly expressed in PTEN‐deficient human GBM cells and tissues and acts as a novel prognostic biomarker and a potential therapeutic candidate.